Primary and secondary coronary heart disease prevention using statins: Is targeting Adam or Eve equally effective?

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 9, 2008, Pages 1437-1440

  Kakafika, Anna I ^a   Athyros, Vasilios G ^a   Tziomalos, Konstantinos ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Men; Risk; Statin; Women

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; EDITORIAL; EPIDEMIC; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MENOPAUSE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PRIMARY PREVENTION; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; TREATMENT OUTCOME; CORONARY ARTERY DISEASE; FEMALE; MALE;

CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; SEX FACTORS; TREATMENT OUTCOME;

EID: 46749093368     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.9.1437     Document Type: Editorial

References (18)

1. Jacobs D, Blackburn H, Higgins M, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046-60
2. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243-52
3. Larosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6
4. Ulmer H, Kelleher C, Diem G, et al. Why Eve is not Adam: prospective follow-up in 149,650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J Womens Health 2004;13:41-53
5. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the US from 1980 through 2002. Concealed leveling of mortality rates. J Am Coll Cardiol 2007;50:2128-32
6. Greenland P, Lloyd-Jones D. Time to end the mixed - and often incorrect - messages about prevention and treatment of atherosclerotic cardiovascular disease. J Am Coll Cardiol 2007;50:2133-5
7. O'Flaherty M, Ford E, Allender S, et al. Coronary heart disease trends in England and Wales from 1984 to 2004: concealed levelling of mortality rates among young adults. Heart 2008;94:178-81
8. National Center for Health Statistics. Health of the United States, 1990. Hyattsville MD: US Department of Health and Human Services, 1991
9. Herrington DM, Vittinghoff E, Lin F, et al; For the HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105:2962-7
10. Wenger NK, Lewis SJ, Welty FK, et al. TNT Steering Committee and Investigators. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart 2008;94:434-9
11. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Effects of statin treatment in men and women with stable coronary heart disease. A subgroup analysis of the GREACE Study. Curr Med Res Opin 2008; in press
12. Athyros VG, Mikhailidis DP, Kakafika AI, et al. Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets 2007;8:483-8
13. Athyros VG, Kakafike AI, Papageorgiou AA, et al. Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J 2007;1:8-14
14. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
15. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
16. Athyros VG, Kakafika AI, Papageorgiou AA, et al.; Greace Study Collaborative Group. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 2007;42:999-1009
17. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am Coll Cardiol 1998;32:140-6
18. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infartion or angina pectoris. Circulation 1997;96:4211-8